Brief Summary
The aim of this study is to assess the progression free survival (PFS) of SABR alone and SABR + 177Lu-prostate-specific membrane antigen (PSMA) in patients with oligometastatic prostate cancer undergoing PSMA positron emission tomography (PET) staging.
Intervention / Treatment
- Drug: 177Lu-PSMA
Inclusion Criteria:
- Male aged 18 years or older at screening
- Patient has provided written informed consent
- Histologically confirmed prostate adenocarcinomacancer arising from mucus-producing glands in organs w
- Prior definitive treatment of the primary with either curative intent radiotherapy and/or surgery
- Patient has 1-5 sites of nodal or bony metastases on 68Ga-PSMA or 18F-DCFPyL PET/CT with a score of 4 or 5 as defined by the E-PSMA criteria
- At least one site of disease with SUVmax greater than the SUVmax of liver on PSMA PET (Ga-68 PSMA 11 or F-18 DCFPYL tracers only)
- Adequate haematological function as defined by:
- Absolute neutrophil count (ANC) ≥1.5 x 109/L
- Platelet count >150x 109/L
- Haemoglobin ≥100 g/L
- Creatinine Clearance ≥ 40mL/min (Cockcroft-Gault formula)
- Assessed as suitable for SABR by a radiation oncologist
- Patients must agree to use an adequate method of contraception
- Have a performance status of 0-1 on the ECOG Performance Scale